What is the global market size of Glioblastoma Multiforme Treatment Market?

Glioblastoma Multiforme Treatment Market size was valued at USD 2.3 billion in 2021 and is poised to grow from USD 2.5 billion in 2022 to USD 4.95 billion by 2030, growing at a CAGR of 8.9% in the forecast period (2023-2030).

What is the key driver of Global Glioblastoma Multiforme Treatment Market?

The increasing occurrence of glioblastoma multiforme, an aggressive brain cancer, is a significant driver of the market. As the prevalence of glioblastoma multiforme treatment continues to rise worldwide, there is a growing need for the development of effective treatment options. This drives the demand for glioblastoma multiforme treatment treatments and fuels market growth.

What is the key market trend for Global Glioblastoma Multiforme Treatment Market?

Increasing Use of Targeted Therapies: Targeted therapies are designed to target specific molecules involved in the growth and spread of glioblastoma multiforme treatment cells. These therapies have shown promise in improving the survival rates of patients with glioblastoma multiforme treatment.

Which region accounted for the largest share in Glioblastoma Multiforme Treatment Market?

The most dominant region in the global glioblastoma multiforme treatment market is North America. This region has a strong presence of key pharmaceutical companies, advanced healthcare infrastructure, and a significant focus on research and development. North America, particularly the US, has witnessed substantial investments in glioblastoma multiforme treatment research and clinical trials. Moreover, the region has a higher prevalence of glioblastoma multiforme treatment cases, driving the demand for effective treatment options. These factors contribute to the dominance of North America in the global glioblastoma multiforme treatment market.

Top Glioblastoma Multiforme Treatment Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Glioblastoma Multiforme Treatment Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Glioblastoma Multiforme Treatment industry players.

Glioblastoma Multiforme Treatment Market Competitive Landscape

The global competitive landscape of the glioblastoma multiforme treatment market is characterised by intense research and development activities, collaborations, and strategic initiatives. glioblastoma multiforme treatment is a highly aggressive and difficult-to-treat brain tumour, and the market for its treatment is witnessing significant advancements and competition. In this competitive landscape, pharmaceutical companies, research institutions, and academic centres are at the forefront of developing innovative treatment approaches for glioblastoma multiforme treatment. These entities focus on improving patient outcomes by exploring novel therapeutic strategies and optimising existing treatment modalities.

Glioblastoma Multiforme Treatment Market Top Player’s Company Profiles

Merck & Co., Inc. (US)

F. Hoffmann-La Roche Ltd (Switzerland)

Novartis AG (Switzerland)

Bristol Myers Squibb Company (US)

Eli Lilly and Company (US)

AbbVie Inc. (US)

Pfizer Inc. (US)

Tocagen Inc. (US)

Kazia Therapeutics Limited (Australia)

DelMar Pharmaceuticals, Inc. (US)

Arbor Pharmaceuticals, LLC (US)

BTG International Ltd (United Kingdom)

Mundipharma International Limited (United Kingdom)

Northwest Biotherapeutics (US)

Orbus Therapeutics Inc. (US)

VBL Therapeutics (Israel)

GT Medical Technologies, Inc. (US)

Oncolys Biopharma Inc. (Japan)

Tocagen (US)

ValiRx Plc (United Kingdom)

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?

REQUEST FREE CUSTOMIZATION

FAQs

Glioblastoma Multiforme Treatment Market size was valued at USD 2.96 Billion in 2024 and is poised to grow from USD 3.23 Billion in 2025 to USD 6.38 Billion by 2033, growing at a CAGR of 8.9% during the forecast period (2026–2033).

Companies such as Merck & Co., Novocure, and Roche lead the highly competitive glioblastoma multiforme treatment industry. To cater for the rapidly growing demand for more potent GBM treatment, these companies are focusing on innovative drugs such as immunotherapies and personalized treatment. Similarly, the market competition and the dynamic market environment with continuous innovation are further influenced by new biotechnological companies that are discovering new technologies aimed at crossing the blood-brain barrier. 'Roche Holding AG ', 'Merck & Co., Inc. ', 'Bristol-Myers Squibb Company ', 'Pfizer Inc. ', 'Novartis AG ', 'Amgen Inc. ', 'Eli Lilly and Company ', 'AbbVie Inc. ', 'Sanofi S.A. ', 'Bayer AG ', 'AstraZeneca plc ', 'Johnson & Johnson ', 'Takeda Pharmaceutical Company Limited ', 'GlaxoSmithKline plc ', 'Celgene Corporation ', 'Teva Pharmaceutical Industries Ltd. ', 'Sun Pharmaceutical Industries Ltd. ', 'Ipsen S.A. ', 'Sumitomo Dainippon Pharma Co., Ltd. ', 'Karyopharm Therapeutics Inc.'

Increased Personalized Medicine Adoption: Personalized or precision medicine has emerged as a major advancement in GBM therapy. This approach helps tailor medicines according to a patient's genetic profile, thereby allowing more specialized and efficient treatment options. Advances in genetics and biomarker testing make it easier to find the treatments that have the best chance of treating the patients.

In 2023, North America had the highest share at 43.4%. The major factors driving the regional market growth are the favorable reimbursement policies, easy accessibility to quality health care facilities, rising awareness about rare conditions, and the support from the government towards the expansion of the healthcare sector. In 2022, the number of new cases of primary brain and spinal cord cancers will be predicted to reach 25,050 people in the US (14,170 men and 10,880 women). The American Cancer Society reveals that 85–90% of all primary CNS cancers occur in the brain. Moreover, 4,170 children in the US under the age of 15 had a diagnosis of brain or central nervous system cancers in 2022.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Luca Giovannini, Marketing Innovation Senior Manager, Trelleborg.

Glioblastoma Multiforme Treatment Market

Report ID: SQMIG35D2105

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE

Top Glioblastoma Multiforme Treatment Companies

Glioblastoma Multiforme Treatment Market Competitive Landscape

FAQs

What is the global market size of Glioblastoma Multiforme Treatment Market?

Who are the key vendors in the Glioblastoma Multiforme Treatment Market?

What is the key driver of Glioblastoma Multiforme Treatment Market?

What is the key market trend for Glioblastoma Multiforme Treatment Market?

Which region accounted for the largest share in Glioblastoma Multiforme Treatment Market?

Request Free Customization